Every 424B that Viridian Therapeutics, Inc. (VRDN) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 424B covers the supplement that carries the terms of a priced offering, so if you follow VRDN and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full VRDN filings page.
Viridian Therapeutics is offering $225.0 million aggregate principal amount of 1.75% convertible senior notes due May 15, 2032, with an underwriter option for an additional $25.0 million. The notes carry an initial conversion rate of 40.5680 shares per $1,000 (initial conversion price ~$24.65 per share), pay interest semi-annually at 1.75%, and may be settled in cash, shares or a combination at the company’s election. The offering is concurrent with a separate public equity offering (aggregate of $125.0 million, or up to $143.75 million if the option is exercised) and Viridian expects to use proceeds, together with the concurrent equity proceeds, to repay the Hercules Loan and fund R&D, market expansion studies and general corporate purposes. The supplement also discloses positive topline REVEAL-2 phase 3 results for elegrobart and an anticipated BLA submission in Q1 2027.
Viridian Therapeutics is offering 7,352,942 shares of common stock at a public offering price of $17.00 per share, expected to raise approximately $117.0 million in net proceeds before expenses (assuming no exercise of the underwriters' option).
Concurrently, Viridian is conducting a separate Concurrent Convertible Notes Offering of 1.75% convertible senior notes due 2032 with an aggregate principal amount of $225.0 million (or $250.0 million if the underwriters’ option is exercised). The company intends to use proceeds to repay the Hercules loan, fund market expansion studies for its TED franchise and advance R&D, and for working capital and general corporate purposes.
Viridian Therapeutics is offering $150.0 million aggregate principal amount of % convertible senior notes due 2032. The notes pay semi‑annual interest, mature on May 15, 2032, and include an underwriter option to purchase up to an additional $22.5 million. Conversions may be settled in cash, shares or a combination and are permitted only upon specified triggers until February 15, 2032, after which conversions are permitted at holder election. The offering is concurrent with a planned $100.0 million equity offering and the company expects to use proceeds to repay its Hercules secured loan, fund market expansion studies for its TED franchise, advance earlier‑stage R&D, and for working capital. Separately, Viridian announced positive topline REVEAL‑2 Phase 3 results for elegrobart (N=204), meeting primary and key secondary endpoints, and plans a BLA submission in Q1 2027.
Viridian Therapeutics is offering an aggregate of $100,000,000 of common stock and Series B non‑voting convertible preferred stock. Each Series B share converts into 66.67 shares of common stock, subject to a Series B Beneficial Ownership Limitation. The company is conducting a concurrent offering of convertible senior notes in an aggregate principal amount of $150,000,000 (with an over-allotment option) that is not contingent on this equity offering. Recent clinical news: topline REVEAL-2 phase 3 results for elegrobart met primary and key secondary endpoints with strong statistical significance (p<0.0001) and the company plans to submit a BLA in Q1 2027. The company’s common stock trades on Nasdaq at $14.06 per share (last reported on May 4, 2026).
Viridian Therapeutics launched a primary offering of 11,425,000 shares of common stock at $22.00 per share. The deal implies a $251,350,000 gross raise, with underwriting fees of $15,081,000, for estimated net proceeds of $236,269,000 before expenses. Underwriters have a 30‑day option to purchase up to 1,713,750 additional shares.
The company plans to use proceeds, together with existing liquidity, to fund commercial launch activities for veligrotug and VRDN‑003, R&D, and for working capital and general corporate purposes.
Viridian noted preliminary cash, cash equivalents and marketable securities of $490.9 million as of September 30, 2025. Recent financing activities include a purchase and sale agreement with DRI providing up to $300 million in consideration, including $55 million received at signing, and an amended Hercules term loan facility of up to $300.0 million.
Nazdaq symbol: VRDN; settlement is expected on or about October 23, 2025.
Viridian Therapeutics (VRDN) launched a preliminary 424B5 for a primary offering of common stock and, in lieu of common for certain investors, Series B non-voting convertible preferred stock. Each Series B share converts into 66.67 shares of common at the holder’s election, subject to a holder‑set Beneficial Ownership Limitation between 4.9% and 19.9%. The company granted underwriters a 30‑day option to buy additional common shares. Net proceeds will support commercial launch activities for veligrotug and VRDN‑003, research and development, and general corporate purposes.
Viridian reported preliminary cash, cash equivalents and marketable securities of $490.9 million as of September 30, 2025. On October 17, 2025, it entered a Purchase and Sale Agreement with DRI for up to $300 million tied to clinical, regulatory and commercial milestones, with tiered U.S. net sales royalties of 7.5% up to $600 million, 0.8% from $600–$900 million, and 0.25% from $900 million–$2 billion. The same day, Viridian amended its Hercules facility to provide up to $300.0 million across tranches, maturing on October 17, 2030, with a floating rate capped at 9.45% and an interest‑only period through October 17, 2029 (extendable upon milestones). Common stock trades on Nasdaq as “VRDN”; Series B has no planned listing.